{"prompt": "['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', '\u00a7', 'If the patient progresses within 24 months after randomization an additional visit (=EOT visit) should be scheduled as timely as possible and the corresponding', 'assessment should be performed.', '#', 'The regular assessments should be performed during the last chemotherapy cycle. If the patient progresses earlier an additional visit (=EOT visit) should be scheduled', 'as timely as possible and the corresponding clinical and laboratory assessments should be performed.', 'A/B', 'To be conducted/assessed/measured for both Arms.', 'A', 'To be conducted/assessed/measured for Arm A.', '(A)', 'To', 'be conducted/assessed/measured for Arm A according to study site standards or if clinically indicated; only to be documented if abnormal.', 'a)', 'Prior and concomitant medication should be reviewed for both Arms to assess eligibility. For Arm A, concomitant medication should also be reviewed during', 'chemotherapy.', 'b)', 'Full physical examination at Screening and after last dose of trial intervention. Directed physical examination during treatment cycles as per study site standards or', 'if clinically indicated. It is recommended to interview patients during the COVID-19 pandemic for respective symptoms including fever, cough and headaches and to', 'initiate comprehensive diagnostic in cases of suspected infections. It is also recommended to assess patients during the COVID-19 pandemic according', 'to', 'the', 'individual policy as regulated by the site, county or state.', 'c)', 'Adverse events should be reviewed for both Arms to assess eligibility. For Arm A, adverse events should be documented during trial intervention at every visit and', 'up', 'to', '4', 'weeks', 'after the last chemotherapy administration. For Arm B, adverse events should be queried at every visit (planned and unplanned) during the first 7', 'months from randomization - but at least twice - by an unbiased open question. Thereafter, adverse events should be queried every three months for both groups', 'by an unbiased open question for up to two years after randomization.', 'd)', 'Height will be measured at Screening only. Vital signs should include temperature, pulse and blood pressure.', 'e)', 'To be repeated prior to the first administration if ECG from screening is older than 8 weeks. To be performed at least once during treatment, i.e. at cycle 7.', 'f)', 'mFOLFOXIRI regimen: Oxaliplatin 85 mg/m\u00b2 2h day 1, Irinotecan 150 mg/m\u00b2 90min day 1, Leucovorin 400 mg/m\u00b2 1-2h day 1, followed by 5-FU 2400 mg/m\u00b2 46h.', 'mFOLFOX-6 regimen: Oxaliplatin 85 mg/m\u00b2 2h day 1, Leucovorin 400 mg/m\u00b2 1-2h day 1, followed by 5-FU 2400 mg/m\u00b2 46h. A 5-FU bolus of 400mg/m\u00b2 prior to the', '5-FU continuous infusion might be administered at the discretion of the investigator.', 'See protocol section 5.2 for dose adjustments in patients with a reduced DPD activity.', 'See protocol section 5.2.3.1 for de-escalated treatment regimens in case of previous oxaliplatin application.', 'g)', 'To', 'be', 'performed', 'in', 'women', 'of childbearing potential only. WOCBP should only be included after a negative highly sensitive urine or serum pregnancy test. This test', 'should be repeated a maximum of 24 hours before study drug administration. Following initiation of treatment, pregnancy testing will be performed every second', 'cycle (at least monthly) during treatment and until the end of relevant systemic exposure to the study medication in accordance with the CTFG guidance on', 'contraception.', 'h)', \"Quick's time [PT/INR], aPTT. Quick's time [PT/INR] during treatment is clinically indicated - and therefore needs to be monitored - in case of concomitant use of 5-\", 'FU and oral anticoagulants.', 'i) These assessments may be performed up to 3 days prior to the treatment administration in order to have the results available on the visit day.', 'Confidential', 'Page 24 of 79']['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', 'j)', 'White Blood Cell (WBC) count with differential & Absolute Neutrophil Count (ANC); Absolute Lymphocyte Count (ALC); Red Blood Cells (RBCs); Platelet count;', 'Hemoglobin; Hematocrit.', 'k)', 'Alkaline phosphatase; Aspartate aminotransferase (AST); Potassium; Sodium; Total Bilirubin; Direct Bilirubin (If total bilirubin is elevated above the upper limit of', 'normal); Creatinine.', 'I)', 'Separate tumor imaging at Screening will only be performed if last available tumor imaging is older than 10 weeks. Carcinoembryonic antigen (CEA) should be', 'determined in addition.', 'm)', 'Tumor imaging during the first 24 months after randomization will be performed every 3 months (q3mo. 2 weeks) calculated from the date of the last imaging.', 'Earlier imaging can be performed if clinically indicated. CEA should be determined in addition to monitor the efficacy of therapy.', 'n)', 'Tumor imaging thereafter will be performed every 6 months (q6mo. + 1 mo.) calculated from the date of the last imaging. Earlier imaging', 'can', 'be', 'performed', 'if', 'clinically indicated. CEA should be determined in addition to monitor the efficacy of therapy.', 'o)', 'If patients consent to accompanying translational research project: Archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not', 'previously irradiated. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred to archived tissue', '(archived specimen 6 months may be acceptable).', 'p)', 'If patients consent to accompanying translational research project: If the patient progresses and a new biopsy is obtained within the clinical routine.', 'q)', 'If patients consent to accompanying translational research project: EDTA blood (10 ml), serum (10 ml) and Streck tubes (10 ml) samples should', 'be', 'taken', 'at', 'Screening and every three months during the first 24 months after randomization and every 6 months thereafter. For patients in Arm A, the blood', 'samples', 'for', 'the', '3', 'months and 6 months timepoint should be drawn prior to the study medication administration (pre-dose).', 'r)', 'Assessment of Covid-19 should be conducted according to the actual pandemic situation AND institutional policy that is applied to any patients that receives', 'FOLFOX/FOLFOXIRI for colorectal cancer outside the trial. This may require assessment of vaccination status, physical examination, anamnesis and Covid-19', 'tests (e.g. antigen test and/or PCR testing). SARS-CoV-2-positive patients should not participate in the trial or chemotherapy application should be delayed as long', 'as the patient is positive for SARS-CoV-2.', 'Confidential', 'Page 25 of 79']\n\n###\n\n", "completion": "END"}